作者: Jacqueline R. Benthuysen , Andrea C. Carrano , Maike Sander
DOI: 10.1172/JCI87439
关键词:
摘要: In the past decade, new approaches have been explored that are aimed at restoring functional β cell mass as a treatment strategy for diabetes. The two most intensely pursued strategies replacement through conversion of other types and regeneration by enhancement replication. approach closest to clinical implementation is cells with human pluripotent stem cell-derived (hPSC-derived) cells, which currently under investigation in trial assess their safety humans. addition, there has success reprogramming developmentally related into cells. Reprogramming could find therapeutic applications inducing vivo or ex followed implantation. Finally, recent studies revealed novel pharmacologic targets stimulating Manipulating these pathways they regulate be promoting expansion residual diabetic patients. Here, we provide an overview progress made toward discuss promises challenges strategies.